Multiple Myeloma Expert Roundtable: Risk Assessment, Minimal Residual Disease, and Precision Medicine

Access Activity

Overview / Abstract:

The clinical multiple myeloma arena has undergone significant advancement in recent years; not only have 10 drugs been added to the armamentarium, but there have been important developments in diagnosis and staging, minimal residual disease (MRD) monitoring, and supportive care. The expansion of clinical options brings both opportunities and challenges for health care providers who see myeloma patients.

In this roundtable, our expert panel discusses the newest evidence regarding the identification and treatment of high-risk disease, MRD measurement and results interpretation, and the clinical implications of the latest precision medicine trial results. This activity includes downloadable resources (including supplemental figures and tables).

Expiration

Dec 27, 2018

Discipline(s)

Nurse Practitioner , Physician CME, Physician Assistant CME

Format

Online

Credits / Hours

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation

ACCME

Presenters / Authors / Faculty

Sagar Lonial, MD, FACP
Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

A. Keith Stewart, MBChB, MRCP, FRCPC, MBA
Carlson and Nelson Endowed Director
Center for Individualized Medicine
Vasek and Anna Maria Polak Professor of Cancer Research
Consultant, Division of Hematology/Oncology
Mayo Clinic
Scottsdale, Arizona

Jeffrey L. Wolf, MD
Clinical Professor of Medicine
Director, Multiple Myeloma Program
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Activity Specialities / Related Topics

Education / Teaching, Hematology, Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

Support for this activity has been provided through educational grants from Amgen, Celgene Corporation, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Keywords / Search Terms

RedMedEd RedMedEd RedMedEd, MMRF, MM, multiple myeloma, risk assessment, minimal residual disease, precision medicine, oncology, hematology, Free, CME, CE, multiple myeloma patients, patient diagnosis, risk stratification, sequencing, options Free CE CME

Access Activity

YouTube Google+ Pinterest Twitter LinkedIn Facebook SlideShare
RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.